BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BIVI BioVie Inc

Post-Mkt 01-22 19:18:09 EST

1.25

+0.05

+4.17%

盘后1.24

-0.01-0.80%

19:16 EST

High1.26	Low1.22	Vol118.23K
Open1.22	D1 Closing1.20	Amplitude3.48%
Mkt Cap9.35M	Tradable Cap9.30M	Total Shares7.48M
T/O146.67K	T/O Rate1.59%	Tradable Shares7.44M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BIVI","market":"US","secType":"STK","nameCN":"BioVie Inc","latestPrice":1.25,"timestamp":1769115600000,"preClose":1.2,"halted":0,"volume":118228,"hourTrading":{"tag":"盘后","latestPrice":1.24,"preClose":1.25,"latestTime":"19:16 EST","volume":189,"amount":235.25000100000003,"timestamp":1769127360567,"change":-0.01,"changeRate":-0.008,"amplitude":0.008},"delay":0,"changeRate":0.041666666666666706,"floatShares":7443300,"shares":7477100,"eps":-8.9218,"marketStatus":"Post-Mkt","change":0.05,"latestTime":"01-22 19:18:09 EST","open":1.2181,"high":1.2599,"low":1.2181,"amount":146666.4803604,"amplitude":0.034833,"askPrice":1.35,"askSize":90,"bidPrice":1.24,"bidSize":40,"shortable":3,"etf":0,"ttmEps":-8.9218,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1769130000000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":1.2,"postHourTrading":{"tag":"盘后","latestPrice":1.24,"preClose":1.25,"latestTime":"19:16 EST","volume":189,"amount":235.25000100000003,"timestamp":1769127360567,"change":-0.01,"changeRate":-0.008,"amplitude":0.008},"volumeRatio":1.229112,"impliedVol":1.6378,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BIVI/tweets","defaultTab":"tweets","newsList":[{"id":"2602977535","title":"BioVie Inc. unveils new data on bezisterim's potential in Parkinson's and Alzheimer's therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2602977535","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602977535?lang=en_us&edition=fundamental","pubTime":"2026-01-11 02:53","pubTimestamp":1768071205,"startTime":"0","endTime":"0","summary":"BioVie Inc. has released a corporate presentation detailing updates on its lead asset, bezisterim , a small molecule targeting TNF-α-mediated inflammation. Clinical trials have shown that bezisterim may reduce inflammation and insulin resistance, improve motor control in Parkinson’s disease patients, and support cognitive function in Alzheimer’s disease. The company is prioritizing the completion of a Phase 2b trial for Parkinson’s disease with topline data expected in the second quarter of 2026, and a Phase 2 exploratory trial for Long Covid, with topline readout anticipated in summer 2026. BioVie also highlighted plans for a Phase 3 ascites trial and a new Phase 3 Alzheimer’s trial, pending additional funding. Bezisterim has demonstrated the ability to cross the blood-brain barrier and has not shown safety issues in pre-clinical and Phase 2 trials. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260110:nNDL7vWGc4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"gpt_icon":0},{"id":"2601364500","title":"BioVie Completes Enrollment for Phase 2 SUNRISE-PD Trial Testing Bezisterim in Early Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364500","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364500?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:02","pubTimestamp":1767877378,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via GlobeNewswire  on January 08, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nNDLWMC6y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014021.USD","IE00B64PRP62.GBP","SG9999014005.SGD","LU2210149790.SGD","BK4585","BIVI","LU2095319765.USD","LU2210150020.SGD","NDAQ","BK4139","SG9999014039.USD","SG9999014013.SGD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112","BK4588","LU0314104364.USD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2601378364","title":"BioVie Inc - Topline Results From Sunrise-Pd Trial Expected in 1H 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2601378364","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601378364?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA3YXWFN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BIVI"],"gpt_icon":0},{"id":"2601364892","title":"BioVie Completes Enrollment in Phase 2 Sunrise-Pd Trial in Early Parkinson’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2601364892","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601364892?lang=en_us&edition=fundamental","pubTime":"2026-01-08 21:00","pubTimestamp":1767877206,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260108:nTUA3YXWFN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"gpt_icon":0},{"id":"2590937365","title":"Halozyme Therapeutics Elects Jim Lang to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2590937365","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590937365?lang=en_us&edition=fundamental","pubTime":"2025-12-09 05:05","pubTimestamp":1765227935,"startTime":"0","endTime":"0","summary":"Halozyme Therapeutics Inc. has announced the election of Jim Lang to its Board of Directors. Lang brings over 30 years of executive experience in healthcare, life sciences, business services, and data analytics. He currently serves on the boards of Biovie, Inc., OptimizeRx Corporation, and EVERSANA, where he was most recently CEO.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Halozyme Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on December 08, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nNDLbYFWX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","OPRX","BK4167","HALO","BIVI","LU0053671581.USD"],"gpt_icon":0},{"id":"2584949069","title":"Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9","url":"https://stock-news.laohu8.com/highlight/detail?id=2584949069","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584949069?lang=en_us&edition=fundamental","pubTime":"2025-11-19 21:00","pubTimestamp":1763557200,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., Nov.  19, 2025  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurod","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/19/3190852/0/en/Join-Biovie-s-Exclusive-Live-Investor-Webinar-and-Q-A-Session-on-December-9.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"gpt_icon":0},{"id":"2578969532","title":"BioVie Inc. Files Initial Statement of Beneficial Ownership for Director Kameel D. Farag","url":"https://stock-news.laohu8.com/highlight/detail?id=2578969532","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578969532?lang=en_us&edition=fundamental","pubTime":"2025-10-28 23:20","pubTimestamp":1761664851,"startTime":"0","endTime":"0","summary":"BioVie Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing names Kameel D. Farag as the beneficial owner, who serves as a Director at BioVie Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 28, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nNDL46VbNs:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"gpt_icon":0},{"id":"2578726456","title":"BioVie Inc. Files Initial Beneficial Ownership Statement for Director Amy Suzon Chappell","url":"https://stock-news.laohu8.com/highlight/detail?id=2578726456","media":"Reuters","labels":["executive","shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578726456?lang=en_us&edition=fundamental","pubTime":"2025-10-28 06:36","pubTimestamp":1761604565,"startTime":"0","endTime":"0","summary":"BioVie Inc. has filed an initial statement of beneficial ownership with the U.S. Securities and Exchange Commission. The filing lists Amy Suzon Chappell as the beneficial owner in her capacity as a director of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 27, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251027:nNDL4Bvd50:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive,shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"gpt_icon":0},{"id":"2570836348","title":"BioVie to Host Live Investor Webinar and Q&A on Oct. 8","url":"https://stock-news.laohu8.com/highlight/detail?id=2570836348","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570836348?lang=en_us&edition=fundamental","pubTime":"2025-09-26 20:00","pubTimestamp":1758888000,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., Sept.  26, 2025  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neuro","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/26/3156974/0/en/BioVie-to-Host-Live-Investor-Webinar-and-Q-A-on-Oct-8.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4181","BK4218","BK4139","HST","BIVI","BK4588","BK4585"],"gpt_icon":0},{"id":"2570044151","title":"BioVie Inc. Announces Date for Upcoming Virtual Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2570044151","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570044151?lang=en_us&edition=fundamental","pubTime":"2025-09-26 05:27","pubTimestamp":1758835660,"startTime":"0","endTime":"0","summary":"BioVie Inc. has scheduled its Annual Meeting of Stockholders to be held virtually on June 12, 2025. During the meeting, shareholders will vote on the election of six directors to serve until the next annual meeting and the ratification of EisnerAmper LLP as the company's independent registered public accounting firm for the fiscal year ending June 30, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on September 25, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250925:nNDL2JS6Ht:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BIVI","BK4139"],"gpt_icon":0},{"id":"2559493859","title":"BioVie Inc. Reports Net Loss of $17.5 Million for Fiscal Year Ending June 30, 2025; R&D Expenses Drop by $13.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2559493859","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559493859?lang=en_us&edition=fundamental","pubTime":"2025-08-16 05:06","pubTimestamp":1755291976,"startTime":"0","endTime":"0","summary":"BioVie Inc., a clinical-stage company focused on developing drug therapies for neurological and neurodegenerative disorders and advanced liver disease, has released its financial results for the fiscal year ending June 30, 2025. The company reported a net loss of approximately $17.5 million and net cash used in operating activities amounting to $19.0 million for the year. To date, BioVie Inc. has not generated any revenues, and no revenues are anticipated in the foreseeable future. The company emphasized the importance of securing additional capital to sustain its operations, with potential future funding sources including sales of equity, obtaining loans, or engaging in other strategic transactions. However, there is significant uncertainty regarding the company's ability to acquire sufficient financing on acceptable terms, which raises substantial doubt about its ability to continue as a going concern. BioVie Inc. continues to pursue its strategic plans, focusing on the development a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250815:nNDL6Dw7wH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"gpt_icon":0},{"id":"2559989266","title":"Cuong V Do, President & CEO of BioVie Inc., Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2559989266","media":"Reuters","labels":["shareholding","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559989266?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:06","pubTimestamp":1755115602,"startTime":"0","endTime":"0","summary":"Cuong V. Do, President & CEO of BioVie Inc., reported an acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioVie Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on August 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250813:nNDL67fcJW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"gpt_icon":0},{"id":"2559816939","title":"BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes","url":"https://stock-news.laohu8.com/highlight/detail?id=2559816939","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559816939?lang=en_us&edition=fundamental","pubTime":"2025-08-14 04:05","pubTimestamp":1755115500,"startTime":"0","endTime":"0","summary":"ADDRESS-LC trial is now enrolling patients with Long COVID-related fatigue and cognitive impairment at sites across the U.S.CARSON CITY, Nev., Aug.  13, 2025  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/13/3132962/0/en/BioVie-Highlighted-ADDRESS-LC-Phase-2-Trial-Design-Exploring-Bezisterim-for-the-Treatment-of-Neurological-Symptoms-of-Long-COVID-at-Keystone-Symposia-on-Long-COVID-and-Other-Post-A.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DOD","BIVI","BK4585","BK4023","BK4166","MT","AD","POST","PD","BK4139","BK4561","LU1169589451.USD","LC","LU1169590202.USD","IE00B29SXL02.USD","BK4006","BK4212","BK4588","IE00B29SXK94.USD"],"gpt_icon":0},{"id":"2558698301","title":"BioVie Inc. Announces Closing of $12 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2558698301","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2558698301?lang=en_us&edition=fundamental","pubTime":"2025-08-12 04:05","pubTimestamp":1754942700,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., Aug.  11, 2025  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic de","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/11/3131256/0/en/BioVie-Inc-Announces-Closing-of-12-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","PD","BK4166","LC","BK4023","LU1169590202.USD","BK4139","BIVI","LU1169589451.USD"],"gpt_icon":0},{"id":"2557590241","title":"BRIEF-Biovie Announces Pricing Of $12 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2557590241","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557590241?lang=en_us&edition=fundamental","pubTime":"2025-08-08 08:43","pubTimestamp":1754613835,"startTime":"0","endTime":"0","summary":"BRIEF-Biovie Announces Pricing Of $12 Million Public OfferingAug 7 (Reuters) - BioVie Inc BIVI.O:BIOVIE INC. ANNOUNCES PRICING OF $12 MILLION PUBLIC OFFERINGBIOVIE INC - UNITS SOLD AT $2.00 EACH, PRE-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nTUA2K8YPJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI"],"gpt_icon":0},{"id":"2557590247","title":"BioVie Inc - Units Sold at $2.00 Each, Pre-Funded Units Less $0.0001","url":"https://stock-news.laohu8.com/highlight/detail?id=2557590247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557590247?lang=en_us&edition=fundamental","pubTime":"2025-08-08 08:43","pubTimestamp":1754613790,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250808:nTUA2K8YPJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BIVI","BK4139"],"gpt_icon":0},{"id":"2557189605","title":"BioVie Inc. Announces Pricing of $12 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2557189605","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557189605?lang=en_us&edition=fundamental","pubTime":"2025-08-08 08:43","pubTimestamp":1754613780,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., Aug.  07, 2025  (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic de","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/08/08/3129900/0/en/BioVie-Inc-Announces-Pricing-of-12-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4588","BK4166","LU1169590202.USD","BK4585","LU1169589451.USD","BIVI","LC","PD","BK4023"],"gpt_icon":0},{"id":"2553788219","title":"BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology","url":"https://stock-news.laohu8.com/highlight/detail?id=2553788219","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553788219?lang=en_us&edition=fundamental","pubTime":"2025-07-24 20:00","pubTimestamp":1753358400,"startTime":"0","endTime":"0","summary":"Bezisterim treatment appears to be associated with changes in DNA methylation of over 100 genes related to aging and diseases of agingCARSON CITY, Nev., July  24, 2025  (GLOBE NEWSWIRE) -- BioVie Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/07/24/3120972/0/en/BioVie-Presented-Data-Highlighting-that-Patients-Treated-with-Bezisterim-Potentially-Experienced-an-Age-Deceleration-Advantage-Compared-to-Placebo-on-10-Different-Biological-Clocks.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BIVI","LU1169589451.USD","BK4023","PD","LU1169590202.USD"],"gpt_icon":0},{"id":"2553253485","title":"Press Release: BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors","url":"https://stock-news.laohu8.com/highlight/detail?id=2553253485","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553253485?lang=en_us&edition=fundamental","pubTime":"2025-07-22 20:00","pubTimestamp":1753185600,"startTime":"0","endTime":"0","summary":"CARSON CITY, Nev., July 22, 2025  -- BioVie Inc.  , a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the appointment of Amy S. Chappell, MD, FAAN, and Kameel D. Farag to its Board of Directors.\"Amy and Kameel each bring an extraordinary combination of strategic vision, operational excellence, and hands-on experience developing and commercializing therapies in complex neurological and chronic diseases,\" said Cuong Do, President and Chief Executive Officer  of BioVie Inc. \"As BioVie continues to advance bezisterim through Phase 2 trials for early Parkinson's disease and long COVID, and plans the next steps in clinical development in our Alzheimer's disease and ascites programs, their expertise will be invaluable in achieving our mission of transforming the treatment of these devastating conditions.\". These appointments come at a time of growing momentum for BioVie. T","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","CNS","MD","IPO","BK4135","BK4232","CEO","R","CFO","BK4196","BK4139","BIVI"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bioviepharma.com","stockEarnings":[{"period":"1week","weight":-0.0083},{"period":"1month","weight":-0.1367},{"period":"3month","weight":-0.3651},{"period":"6month","weight":-0.8396},{"period":"1year","weight":-0.9415},{"period":"ytd","weight":0.0345}],"compareEarnings":[{"period":"1week","weight":-0.0072},{"period":"1month","weight":0.0008},{"period":"3month","weight":0.0203},{"period":"6month","weight":0.0758},{"period":"1year","weight":0.1366},{"period":"ytd","weight":0.0051}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.","yearOnYearQuotes":[{"month":1,"riseRate":0.375,"avgChangeRate":0.001141},{"month":2,"riseRate":0.428571,"avgChangeRate":0.266661},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.043931},{"month":4,"riseRate":0.285714,"avgChangeRate":0.003163},{"month":5,"riseRate":0.25,"avgChangeRate":-0.106717},{"month":6,"riseRate":0.5,"avgChangeRate":0.43449},{"month":7,"riseRate":0.5,"avgChangeRate":0.320477},{"month":8,"riseRate":0.25,"avgChangeRate":-0.209827},{"month":9,"riseRate":0.375,"avgChangeRate":-0.162595},{"month":10,"riseRate":0.375,"avgChangeRate":0.201324},{"month":11,"riseRate":0.5,"avgChangeRate":-0.005666},{"month":12,"riseRate":0.25,"avgChangeRate":-0.131533}],"exchange":"NASDAQ","name":"BioVie Inc","nameEN":"BioVie Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BioVie Inc(BIVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BioVie Inc,BIVI,BioVie Inc股票,BioVie Inc股票老虎,BioVie Inc股票老虎国际,BioVie Inc行情,BioVie Inc股票行情,BioVie Inc股价,BioVie Inc股市,BioVie Inc股票价格,BioVie Inc股票交易,BioVie Inc股票购买,BioVie Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BioVie Inc(BIVI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BioVie Inc(BIVI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction